CIR Expert Panel Announces New Blood Ahead Of 161st Meeting
Expect new faces in coming meetings of the US-based CIR’s Expert Panel for Cosmetic Ingredient Safety, which may tackle reviews of prostaglandin analogs and skin-lightening kojic acid on top of its usual slate of programmed safety assessments.
You may also be interested in...
CIR’s 161st Expert Panel Meeting: Much Ado About Airbrush Cosmetics; Prostaglandins Make 2023 Priorities
Exactly what is in airbrush-delivered cosmetics, and how they are used by consumers, are not well understood by Cosmetic Ingredient Review, its expert panel, or the US FDA. At their June meeting, CIR’s independent experts debated who should be responsible for assessing airbrush cosmetics and how safety unknowns should be communicated.
Making Cosmetics Reform Beneficial For All; Former FDA Cosmetics Director Yearns For ‘Serious Sit-Down’
Federal legislative reform is an historic opportunity not only to strengthen the US FDA’s oversight of the cosmetics sector, but also to modernize the industry and its value proposition to consumers. John Bailey, independent advisor for cosmetics and colors at EAS Consulting Group, is confident there’s a way to do all, but "serious" stakeholder negotiations are needed.
The US-based Cosmetic Ingredient Review’s independent experts finalized four ingredient safety reports at its 7-8 March meeting, advanced nine tentative assessments, and issued two insufficient data announcements. The panel continues to face challenges in assessing ingredients used in airbrush applications and decided against prioritizing review of eyelash-"enhancing" prostaglandin analogues.